Cipla, a leading Indian pharmaceutical company, is charting its future growth strategy with a focus on innovation, complex generics, and biosimilars. Managing Director Achin Gupta stated that the company plans to file between 40-50 global products over the next three years, including four respiratory launches and three peptide products in the U.S. this year. Cipla is also concentrating on chronic conditions such as diabetes, cardiovascular diseases, and obesity, aiming to strengthen its market presence in these areas. The company has plans to develop one to two biosimilars each year for the next five to six years, targeting a total of around 10 products. Innovation plays a crucial role in Cipla's future, with Gupta highlighting ongoing projects in stem cells and mRNA technology. Furthermore, Cipla aims to enhance its AI capabilities to improve productivity. While large acquisitions in India are not on the agenda, Cipla is looking for opportunities to acquire differentiated assets in North America and Europe to bolster its product pipeline and market presence.